Young Kwang Chae, MD, MPH, MBA, National Cancer Institute, Bethesda, MD, provides an overview of the Phase II SWOG 1609 (DART) trial (NCT02834013) of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors. This basket trial is investigating immunotherapy responses in various histologies. With over 50 different cohorts of rare tumors, the trial aims to identify which histologies show a positive signal in response to immunotherapy. Particularly, interesting results have been observed in desmoid and vulvar tumors, the results of which were presented at ASCO 2023. The trial also includes translational medicine projects to study biomarkers of response in these rare tumors. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
